Copyright
©2013 Baishideng Publishing Group Co.
World J Diabetes. Dec 15, 2013; 4(6): 358-364
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.358
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.358
Table 1 Demographics and baseline characteristics
Vildagliptin group(n = 55) | Sulfonylureagroup (n = 42) | |
Age (yr) | 51.0 ± 8.8 | 50.9 ± 9.1 |
≥ 65 yr | 4 (7.3) | 4 (9.5) |
Weight, kg | 69.1 ± 10.9 | 67.4 ± 10.0 |
Height, cm | 159.7 ± 8.1 | 158.4 ± 9.8 |
HbA1c, % (mmol/mol) | 8.75 ± 1.27 (72.10 ± 13.90) | 8.64 ± 1.57 (70.92 ± 17.14) |
HbA1c < 7.0% (< 53.0 mmol/mol) | 3 (5.5) | 6 (14.3) |
FPG, mg/dL | 140.2 ± 42.0 | 162.1 ± 48.2 |
PPG, mg/dL | 212.2 ± 52.2 | 220.6 ± 54.0 |
Patients receiving metformin, n (%) | 38 (69.1) | 30 (71.4) |
Mean doses of sulfonylureas, mg/d | ||
Glibenclamide (n = 7) | - | 10 |
Gliclazide (n = 10) | - | 106 |
Glimepiride (n = 23) | - | 4.2 |
Glipizide (n = 2) | - | 10 |
-
Citation: Shete A, Shaikh A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, Khanna R, Majid S, Rasheed SA, Shaikh S, Rahman T. Vildagliptin
vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes 2013; 4(6): 358-364 - URL: https://www.wjgnet.com/1948-9358/full/v4/i6/358.htm
- DOI: https://dx.doi.org/10.4239/wjd.v4.i6.358